Holen Sie sich die Stockscreener-App
0.1003
0.10%
0.0001
Handel nachbörslich:
.10
-0.0003
-0.30%
Schlusskurs vom Vortag:
$0.1002
Offen:
$0.11
24-Stunden-Volumen:
21,206
Relative Volume:
1.87
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.93%
1M Leistung:
+0.20%
6M Leistung:
-26.90%
1J Leistung:
+181.74%
1-Tages-Spanne:
$0.1003
$0.11
1-Wochen-Bereich:
$0.1002
$0.14
52-Wochen-Spanne:
$0.0201
$34.93
Geovax Labs Inc Stock (GOVXW) Company Profile
Firmenname
Geovax Labs Inc
Sektor
Branche
Telefon
678 384 7220
Adresse
1900 Lake Park Drive, Suite 380, Smyrna
Vergleichen Sie GOVXW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOVXW
Geovax Labs Inc
|
0.1003 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Geovax Labs Inc Aktie (GOVXW) Neueste Nachrichten
Stock Surge: Geovax Labs Inc (GOVX) Closes at 1.77, Marking a -7.33 Increase/Decrease - The Dwinnex
Analysts review Geovax Labs Inc’s rating - Knox Daily
GeoVax to Present Strategic Vision for Cancer and Infectious Disease Treatments at Major Biotech Conference - Citybuzz
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Trump's Stargate Initiative: A New Era For Healthcare Innovation - Evrim Ağacı
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative - Yahoo Finance
GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
GeoVax Labs (NASDAQ:GOVXW) Shares Down 11.3% – Here’s Why - Defense World
GeoVax shareholders approve warrant exercises - MSN
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability - Yahoo Finance
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Labs Stockholders Approve Warrant Exercise Proposals - Defense World
GeoVax shareholders approve warrant exercises By Investing.com - Investing.com Australia
D. Boral Capital Reaffirms “Buy” Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial - Yahoo Finance
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now - GlobeNewswire Inc.
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024 - Yahoo Finance
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025 - Yahoo Finance
Contrasting GeoVax Labs (NASDAQ:GOVX) & Silverback Therapeutics (NASDAQ:SBTX) - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
GeoVax adjourns Special Meeting due to low quorum - Investing.com
GeoVax adjourns Special Meeting due to low quorum By Investing.com - Investing.com Australia
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent - The Manila Times
GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan
GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78 - MSN
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Geovax Labs (FRA:E8LA) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Geovax Labs (STU:E8LA) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com
Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN
3 Penny Stocks Ready to Break Out in 2025 - sharewise
Geovax Labs (STU:E8LA) Momentum Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference - GlobeNewswire
GeoVax CEO to Present COVID-19 Vaccine & Cancer Therapy Updates at NobleCon20 | GOVX Stock News - StockTitan
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Q4 EPS Estimates for GeoVax Labs Lifted by Noble Financial - Defense World
GeoVax Announces Positive Interim Data Review for Phase 2 - GlobeNewswire
GeoVax regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia
GeoVax regains compliance with Nasdaq listing standards - Investing.com India
GeoVax reports progress in CLL vaccine booster trial - Investing.com India
GeoVax reports progress in CLL vaccine booster trial By Investing.com - Investing.com Canada
GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology - TipRanks
GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine | GOVX Stock News - StockTitan
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - The Manila Times
Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World
Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia
Finanzdaten der Geovax Labs Inc-Aktie (GOVXW)
Es liegen keine Finanzdaten für Geovax Labs Inc (GOVXW) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.02%
0.32%
Kapitalisierung:
|
Volumen (24h):